
Ipililumumab's role in treating melanoma will change, as the immunotherapy will likely become part of different combinations than we see today.
Mary Caffrey is the Executive Editor for The American Journal of Managed Care® (AJMC®). She joined AJMC® in 2013 and is the primary staff editor for Evidence-Based Oncology, the multistakeholder publication that reaches 22,000+ oncology providers, policy makers and formulary decision makers. She is also part of the team that oversees speaker recruitment and panel preparations for AJMC®'s premier annual oncology meeting, Patient-Centered Oncology Care®. For more than a decade, Mary has covered ASCO, ASH, ACC and other leading scientific meetings for AJMC readers.
Mary has a BA in communications and philosophy from Loyola University New Orleans. You can connect with Mary on LinkedIn.

Ipililumumab's role in treating melanoma will change, as the immunotherapy will likely become part of different combinations than we see today.

Two stories--of taking part in clinical trials, and of serving as a voice for patients among scientists who run them--highlight how the advances in cancer are built on the trust between those living with the disease and the clinicians on the frontiers of care.

A survey of healthcare executives finds that ongoing issues with interoperability are holding back the transition to value-based reimbursement mechanisms. Humana's Chief Medical Officer, Roy A. Beveridge, MD, said the healthcare system must demand the same level of seamlessness seen in the banking industry.

Flatiron Health expects to maintain its current business model in the transaction.

The study used a claims database to examine records from patients who switched between long-acting insulins.

Such a large drop in Americans' sense of well-being in their daily lives in a time of economic good fortune is unprecedented, index organizers say.

Of the 262 patients with type 2 diabetes in the intervention, 83% stuck with it through the first year, despite significant requirements.

Coverage of our peer-reviewed research and news reporting in the healthcare and mainstream press.

Critics of the non-emergency transportation benefit cite the potential for fraud, but others say transportation often tops the list of reasons people miss medical appointments.

Despite an official policy since early 2017 that calls for Medicare to cover CGM for certain beneficiaries with diabetes, an attorney who won a landmark case prior to the policy change reports that beneficiaries are still being denied coverage.

Trump's calls for cracking down on drug prices and enacting right-to-try legislation bring a reaction on Wall Street, but speaking for less than a minute on on the opioid crisis brings a different response from Democratic lawmakers.

President Donald Trump returned to a popular campaign theme in Tuesday’s State of the Union address when he vowed to bring down the high cost of prescription drugs.

Empagliflozin (Jardiance) and another SGLT2 inhibitor, canagliflozin (Invokana) have been competing aggressively; both have clinical trial results showing cardiovascular benefits.

Officials at Omada Health said the PREDICTS trial was planned long before CMS decided not to include virtual providers in this spring's launch of the Medicare Diabetes Prevention Program. But a spokesperson said the company hopes the growing body of evidence in support of virtual programs will "assuage any concerns."

Via Pathways covers more than 2000 different patient representations in cancer care.

The annual meeting of the American College of Cardiology (ACC), which runs March 10-12, 2018, in Orlando, Florida, will open with cardiovascular outcomes results for the PCSK9 inhibitor alirocumab (Praluent). The meeting also features updates on anti-inflammatory drugs, the use of SGLT2 inhibitors in heart failure, and how cardiology is shifting to new healthcare delivery models.

Researchers were especially concerned about barriers for patients with familial hypercholesterolemia, whose needs would seem clear cut but who nonetheless faced costly hurdles, such as genetic testing.

The pairing will give employers and health plans "holistic" solutions for chronic disease management, according to CEOs of the companies.

New Jersey's largest payer will track a host of measures, including some that will evaluate the quality of end-of-life care.

Chris Christie vowed to devote his final year as New Jersey's governor to fighting opioid abuse. A veteran advocate says Christie has accomplished more than people realize, and his use of the bully pulpit should not be underestimated.

The approval comes a day after the Trump administration released a guidance for states that want to require work from able-bodied Medicaid recipients. Current CMS Administrator Seema Verma designed the Kentucky program when she was a consultant but recused herself from the application.


The same mechanisms that cause those with long-term HIV infection to suffer higher rates of heart attacks or strokes put children born with disease at early risk of cardiovascular disease, according to a new study.

The long-awaited guidance allows states to seek waivers that require able-bodied adults to show they are working, receiving education, serving as a caregiver, volunteering, or receiving substance abuse treatment in order to be eligible for Medicaid.

Brenda Schmidt, CEO of Solera Health, discusses the historic launch of the Medicare Diabetes Prevention Program scheduled for this April and how her company is helping providers and other stakeholders get ready.

The announcement comes after CMS canceled an Obama-era proposal for mandatory bundled payments in cardiac care, as well as a mandatory expansion of a program in joint replacements.

The announcement comes after CMS canceled an Obama-era proposal for mandatory bundled payments in cardiac care, as well as a mandatory expansion of a program in joint replacements.

The study confirms reports heard throughout the country in the years since implementation of the Affordable Care Act.

The factory-calibrated continuous glucose monitoring (CGM) system is being touted as less expensive, and a spokeswoman said it will not require bundling with a meter, which is required for a competitor.

Dexcom Executive Vice President and Chief Commercial Officer RIck Doubleday visited The American Journal of Managed Care® to discuss Medicare reimbursement for the Dexcom G5 and a new partnership with Fitbit.

259 Prospect Plains Rd, Bldg H
Cranbury, NJ 08512
© 2025 MJH Life Sciences®
All rights reserved.
